In recent years, much of the literature has identified the tight correlation between tau pathology and the clinical progression of AD, and therapeutic strategies aimed at targeting toxic tau proteins are increasingly recognized as promising approaches [24,25,26]. This evidence concerns the gene MAPT and Alzheimer disease.